Roksatidin

Roksatidin acetat
(IUPAC) ime
	2-okso-2-(3-[3-(piperidin-1-ilmetil)fenoksi]propilamino)etil acetat
Klinički podaci
Identifikatori
CAS broj	78628-28-1
ATC kod	A02BA06
PubChem	5105
DrugBank	DB08806
ChemSpider	4926
UNII	IV9VHT3YUM
KEGG	D08495
ChEMBL	CHEMBL46102
Hemijski podaci
Formula	C19H28N2O4
Mol. masa	348,437 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C19H28N2O4/c1-16(22)25-15-19(23)20-9-6-12-24-18-8-5-7-17(13-18)14-21-10-3-2-4-11-21/h5,7-8,13H,2-4,6,9-12,14-15H2,1H3,(H,20,23) ; Key: SMTZFNFIKUPEJC-UHFFFAOYSA-N
Farmakokinetički podaci
Bioraspoloživost	80–90%
Vezivanje za proteine plazme	5–7%
Metabolizam	Hepatička deacetilacija; Minje učešće CYP2D6 i CYP2A6
Poluvreme eliminacije	5–7 sata
Izlučivanje	Renalno
Farmakoinformacioni podaci
Trudnoća	?
Pravni status
Način primene	Oralno

Roksatidin acetat je specifični i kompetitivni antagonist H₂ receptora. Antisekretorno dejstvo roksatidin acetata je posredovano njegovim glavnim metabolitom, roksatidinom.

Struktura roksatidina, metabolita i aktivnog farmaceutskog sastojka.

Farmakodinamičke studije su pokazale da je 150 mg roksatidin acetata optimalno u suzbijanju sekrecije želudačne kiseline.^[6]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Murdoch D, McTavish D (1991). „Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders”. Drugs 42 (2): 240-260. PMID 1717223.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[6] Murdoch D, McTavish D (1991). „Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders”. Drugs 42 (2): 240-260. PMID 1717223.

[1]